|
1.
|
Bast RC Jr, Hennessy B and Mills GB: The
biology of ovarian cancer: new opportunities for translation. Nat
Rev Cancer. 9:415–428. 2009. View
Article : Google Scholar : PubMed/NCBI
|
|
2.
|
Lengyel E: Ovarian cancer development and
metastasis. Am J Pathol. 177:1053–1064. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
3.
|
Ahmed N, Thompson EW and Quinn MA:
Epithelialmesenchymal interconversions in normal ovarian surface
epithelium and ovarian carcinomas: an exception to the norm. J Cell
Physiol. 13:581–588. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
4.
|
Roy R, Yang J and Moses MA: Matrix
metalloproteinases as novel biomarkers and potential therapeutic
targets in human cancer. J Clin Oncol. 27:5287–5297. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
5.
|
Sillanpää S, Anttila M, Voutilainen K,
Ropponen K, Turpeenniemi-Hujanen T, Puistola U, Tammi R, Tammi M,
Sironen R, Saarikoski S and Kosma VM: Prognostic significance of
matrix metalloproteinase-9 (MMP-9) in epithelial ovarian cancer.
Gynecol Oncol. 104:296–303. 2007.PubMed/NCBI
|
|
6.
|
Kenny HA, Kaur S, Coussens LM and Lengyel
E: The initial steps of ovarian cancer cell metastasis are mediated
by MMP-2 cleavage of vitronectin and fibronectin. J Clin Invest.
118:1367–1379. 2008. View
Article : Google Scholar : PubMed/NCBI
|
|
7.
|
Kenny HA and Lengyel E: MMP-2 functions as
an early response protein in ovarian cancer metastasis. Cell Cycle.
8:683–688. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
8.
|
Burleson KM, Casey RC, Skubitz KM,
Pambuccian SE, Oegema TR Jr and Skubitz AP: Ovarian carcinoma
ascites spheroids adhere to extracellular matrix components and
mesothelial cell monolayers. Gynecol Oncol. 93:170–181. 2004.
View Article : Google Scholar
|
|
9.
|
Burleson KM, Hansen LK and Skubitz AP:
Ovarian carcinoma spheroids disaggregate on type I collagen and
invade live human mesothelial cell monolayers. Clin Exp Metastasis.
21:685–697. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
10.
|
Iwanicki MP, Davidowitz RA, Ng MR, Besser
A, Muranen T, Merritt M, Danuser G, Ince TA and Brugge JS: Ovarian
cancer spheroids use myosin-generated force to clear the
mesothelium. Cancer Discov. 1:144–157. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
11.
|
Vigushin DM, Ali S, Pace PE, Mirsaidi N,
Ito K, Adcock I and Coombes RC: Trichostatin A is a histone
deacetylase inhibitor with potent antitumor activity against breast
cancer in vivo. Clin Cancer Res. 7:971–976. 2001.PubMed/NCBI
|
|
12.
|
Kristensen LS, Nielsen HM and Hansen LL:
Epigenetics and cancer treatment. Eur J Pharmacol. 625:131–142.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
13.
|
Chen MY, Liao WS, Lu Z, Bornmann WG,
Hennessey V, Washington MN, Rosner GL, Yu Y, Ahmed AA and Bast RC
Jr: Decitabine and suberoylanilide hydroxamic acid (SAHA) inhibit
growth of ovarian cancer cell lines and xenografts while inducing
expression of imprinted tumor suppressor genes, apoptosis, G2/M
arrest and autophagy. Cancer. 117:4424–4438. 2011. View Article : Google Scholar
|
|
14.
|
Li Y, Hu W, Shen DY, Kavanagh JJ and Fu S:
Azacitidine enhances sensitivity of platinum-resistant ovarian
cancer cells to carboplatin through induction of apoptosis. Am J
Obstet Gynecol. 200:177 e1:–e9. 2009.PubMed/NCBI
|
|
15.
|
Sonnemann J, Gänge J, Pilz S, Stötzer C,
Ohlinger R, Belau A, Lorenz G and Beck JF: Comparative evaluation
of the treatment efficacy of suberoylanilide hydroxamic acid (SAHA)
and paclitaxel in ovarian cancer cell lines and primary ovarian
cancer cells from patients. BMC Cancer. 6:1832006. View Article : Google Scholar : PubMed/NCBI
|
|
16.
|
Dietrich CS III, Greenberg VL, DeSimone
CP, Modesitt SC, van Nagell JR, Craven R and Zimmer SG:
Suberoylanilide hydroxamic acid (SAHA) potentiates paclitaxel
induced apoptosis in ovarian cancer cell lines. Gynecol Oncol.
116:126–130. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
17.
|
Chou TC: Drug combination studies and
their synergy quantification using the Chou-Talalay method. Cancer
Res. 70:440–446. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
18.
|
Baba T, Convery PA, Matsumura N, Whitaker
RS, Kondoh E, Perry T, Huang Z, Bentley RC, Mori S, Fujii S, Marks
JR, Berchuck A and Murphy SK: Epigenetic regulation of CD133 and
tumorigenicity of CD133+ ovarian cancer cells. Oncogene.
28:209–218. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
19.
|
Shield K, Ackland ML, Ahmed N and Rice GE:
Multicellular spheroids in ovarian cancer metastases: biology and
pathology. Gynecol Oncol. 113:143–148. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
20.
|
Lin T, Ponn A, Hu X, Law BK and Lu J:
Requirement of the histone demethylase LSD1 in Snai1-mediated
transcriptional repression during epithelial-mesenchymal
transition. Oncogene. 29:4896–4904. 2010. View Article : Google Scholar
|
|
21.
|
Peinado H, Ballestar E, Esteller M and
Cano A: Snail mediates E-cadherin repression by the recruitment of
the Sin3A/histone deacetylase 1 (HDAC1)/HDAC2 complex. Mol Cell
Biol. 24:306–319. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
22.
|
Yang J, Mani SA, Donaher JL, Ramaswamy S,
Itzykson RA, Come C, Savagner P, Gitelman I, Richardson A and
Weinberg RA: Twist, a master regulator of morphogenesis, plays an
essential role in tumor metastasis. Cell. 117:927–939. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
23.
|
Vesuna F, van Diest P, Chen JH and Raman
V: Twist is a transcriptional repressor of E-cadherin gene
expression in breast cancer. Biochem Biophys Res Commun.
367:235–241. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
24.
|
Rahnama F, Shafiei F, Gluckman PD,
Mitchell MD and Lobie PE: Epigenetic regulation of human
trophoblastic cell migration and invasion. Endocrinology.
147:5275–5283. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
25.
|
Bergers G, Brekken R, McMahon G, Vu TH,
Itoh T, Tamaki K, Tanzawa K, Thorpe P, Itohara S, Werb Z and
Hanahan D: Matrix metalloproteinase-9 triggers the angiogenic
switch during carcinogenesis. Nat Cell Biol. 2:737–744. 2000.
View Article : Google Scholar : PubMed/NCBI
|
|
26.
|
Chen H, Hardy TM and Tollefsbol TO:
Epigenomics of ovarian cancer and its chemoprevention. Front Genet.
2:672011. View Article : Google Scholar : PubMed/NCBI
|
|
27.
|
Balch C, Huang TH, Brown R and Nephew KP:
The epigenetics of ovarian cancer drug resistance and
resensitization. Am J Obstet Gynecol. 191:1552–1572. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
28.
|
Balch C, Fang F, Matei DE, Huang TH and
Nephew KP: Minireview: epigenetic changes in ovarian cancer.
Endocrinology. 150:4003–4011. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
29.
|
Yoo CB and Jones PA: Epigenetic therapy of
cancer: past, present and future. Nat Rev Drug Discov. 5:37–50.
2006. View
Article : Google Scholar : PubMed/NCBI
|
|
30.
|
Metzger E, Wissmann M, Yin N, Müller JM,
Schneider R, Peters AH, Günther T, Buettner R and Schüle R: LSD1
demethylates repressive histone marks to promote androgen-receptor
dependent transcription. Nature. 437:436–439. 2005.PubMed/NCBI
|
